DIABETIC MACULAR OEDEMA
A randomised study involving 111 eyes of 105 patients with diabetic macular oedema showed that, compared with baseline values, visual acuity improved significantly more at three and six months among patients receiving triamcinolone alone or in combination with bevacizumab than in eyes receiving bevacizumab alone. All three treatments produce significant reductions in central macular thickness throughout follow-up, with greater reductions during the first months of therapy in the triamcinolone groups. However, by 12 months the groups had statistically similar results in terms of both macular thickness and visual acuity
(Lim et al, Ophthalmologica 2012; 227: 00-106).
Latest Articles
Addressing Postoperative Visual Complications
Managing aberrations after laser refractive surgery requires a multi-layered approach.
3D Printing Helps Transform Ukrainian Eye Care
The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.
Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation
Emerging Microbial Trends That Could Affect Your Practices
A triptych of challenges paints a concerning picture for ophthalmologists across the globe.
Improving Outcomes with Laser-Assisted Surgery
Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.
Could the Corneal Transplant Pool Increase?
Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.
Matching Premium IOLs to Visual Lifestyles
From monofocal to full-range solutions, each practice needs comprehensive understanding.
Going Dutch on Acanthamoeba Keratitis
A world-first trial suggests a new medication could beat the disease.
Avoiding Intracorneal Ring Segment Complications
Femtosecond lasers are helping improve refractive results with fewer problems.